[Critical analysis of noninflammatory treatments of sepsis: lessons learned from previous trials]

Area of Science:

• Critical care medicine
• Immunology
• Clinical trial methodology

Context:

• Severe sepsis and septic shock are life-threatening conditions with high mortality rates.
• Numerous immunomodulatory therapies have been investigated for these conditions.
• Historically, these therapies have failed to demonstrate significant survival benefits.

Purpose:

• To critically review the existing literature on immunomodulatory therapies for severe sepsis and septic shock.
• To identify common biases and methodological flaws in clinical trials of these therapies.
• To propose recommendations for designing more robust and informative future clinical trials.

Summary:

• A comprehensive review of immunomodulatory therapies for severe sepsis and septic shock revealed a consistent lack of efficacy in reducing mortality.
• Key challenges identified include a poor understanding of the complex immune response in sepsis, pharmacological errors, patient selection bias, and issues with data evaluation and interpretation.
• These methodological shortcomings have hampered the development of effective treatments.

Impact:

• This analysis underscores the need for improved clinical trial design in sepsis research.
• Recommendations focus on enhancing patient selection, standardizing treatment protocols, and refining outcome assessments.
• Future trials adhering to these guidelines may yield more reliable data and advance the development of effective sepsis therapies.